Combined effect of polarity and pH on the chromatographic behavior of some angiotensin II receptor antagonists and optimization of their determination in pharmaceutical dosage forms

ÇUBUK DEMİRALAY E., Cubuk B., ÖZKAN S. A., Alsancak G.

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol.53, no.3, pp.475-482, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 3
  • Publication Date: 2010
  • Doi Number: 10.1016/j.jpba.2010.05.020
  • Journal Name: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.475-482
  • Keywords: Angiotensin II receptor antagonist, Chromatographic retention modelling, LC, Polarity parameter, pK(a), Method validation, PERFORMANCE LIQUID-CHROMATOGRAPHY, REFERENCE VALUE STANDARDS, SOLVENT COMPOSITION, POLYPHENOLIC ACIDS, MODELING RETENTION, PK(A) VALUES, WATER, HYDROCHLOROTHIAZIDE, PREDICTION, CONSTANTS
  • Ankara University Affiliated: Yes

Abstract

In the present study, the combined effect of mobile phase polarity and pH on retention behavior of some ARA-IIs (irbesartan, losartan, valsartan and telmisartan) is investigated The linear relationships established between retention factors of the species and the polarity parameter of the mobile phase has proved to predict accurately retention in LC as a function of the acetonitrile content (50%, 55%, 60%, v/v) The suggested model uses the pH value in the acetonitrile-water mixture as mobile phase instead of pH value in water and takes into account the effect of activity coefficients. Moreover, correlation between retention and the mobile phase pH can be established allowing prediction of the retention behavior as a function of the mobile phase pH The model can be used to estimate the pK(a) in an acetonitrile percentage between 50% and 60%, at 30 degrees C The developed method was successfully applied to both the simultaneous separation of these drug-active compounds and individual determination in their commercial pharmaceutical dosage forms. (c) 2010 Elsevier B.V All rights reserved.